BRIDGEWATER, N.J., Feb. 15, 2019 /PRNewswire/ -- Insmed Incorporated
(Nasdaq: INSM), a global biopharmaceutical company focused on the
unmet needs of patients with rare diseases, today announced that it
will release its fourth quarter and year-end financial results on
Friday, February 22, 2019.
Insmed management will host a conference call for investors
beginning at 8:30 a.m. ET on Friday,
February 22, 2019 to discuss the financial results and
provide a business update.
Shareholders and other interested parties may participate in the
conference call by dialing (888) 317-6003 (domestic) or (412)
317-6061 (international) and referencing conference ID number
5106939. The call will also be webcast live on the company's
website at www.insmed.com.
A replay of the conference call will be accessible approximately
one hour after its completion through March
1, 2019 by dialing (877) 344-7529 (domestic) or (412)
317-0088 (international) and referencing replay access code
10128650. A webcast of the call will also be archived for 90 days
under the Investor Relations section of the company's website at
www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is ARIKAYCE®
(amikacin liposome inhalation suspension), which is approved in
the United States for the
treatment of Mycobacterium avium complex (MAC) lung disease as part
of a combination antibacterial drug regimen for adult patients with
limited or no alternative treatment options. MAC lung disease is a
rare and often chronic infection that can cause irreversible lung
damage and can be fatal. Insmed's earlier-stage clinical pipeline
includes INS1007, a novel oral reversible inhibitor of dipeptidyl
peptidase 1 with therapeutic potential in non-cystic fibrosis
bronchiectasis and other inflammatory diseases, and INS1009, an
inhaled formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more information,
visit www.insmed.com.
Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
blaine.davis@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-fourth-quarter-and-full-year-2018-financial-results-conference-call-on-friday-february-22-2019-300796412.html
SOURCE Insmed Incorporated